About Us
About the COVID-19 Prevention Network (CoVPN)
The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2. The CoVPN is comprised of the partners listed below.
Our Mission
To conduct Phase 3 efficacy trials for COVID-19 vaccines and monoclonal antibodies. The CoVPN will work to develop and conduct studies to ensure rapid and thorough evaluation of US government-sponsored COVID-19 vaccines and monoclonal antibodies for the prevention of COVID-19 disease.
Community and Stakeholder Engagement
Read the COVPN Community and Stakeholder Engagement Strategic Plan.
Planning a COVID-19 research educational event for your community?
The CoVPN is happy to provide a speaker with knowledge and expertise in COVID-19 research to speak at your event. Complete our Speaker Request Form and a CoVPN representative will connect you with one of our speakers
CoVPN Faith Initiative
Why is the COVID-19 Prevention Network launching a faith-based initiative?
With Black/African American, Latinx, and American Indian/Alaska Native/Native Hawaiian communities throughout the United States disproportionately impacted by COVID-19 disease and death, it is critical that clinical trials enroll – more accurately, prioritize – participants representative of these populations.
To this end, the CoVPN has established a national, faith-based program in the U.S. called the CoVPN Faith Initiative to enhance trust and meaningful engagement in key communities throughout the U.S. and provide accurate and updated information about COVID-19 and CoVPN clinical trials. Rev. Edwin C. Sanders, II, of the Metropolitan International Church in Nashville, TN, will lead the initiative, coordinating the work of seven “faith ambassadors” and more than 30 clergy-consultants from the Black, Latinx and American Indian/Alaska Native communities throughout the U.S. These faith leaders are charged with implementing a faith-focused COVID-19 and CoVPN education program in the U.S. that supports inclusive engagement of members in key communities.
Partners
HIV Vaccine Trials Network
The HIV Vaccine Trials Network (HVTN) is the world’s largest publicly funded international collaboration focused on the development of vaccines to prevent HIV/AIDS.
HIV Prevention Trials Network
The HIV Prevention Trials Network (HPTN) develops and tests the safety and efficacy of non-vaccine interventions designed to prevent the transmission of HIV.
Infectious Disease Clinical Research Consortium
NIAID established the Infectious Diseases Clinical Research Consortium in 2019. It encompasses the Institute’s long-standing Vaccine and Treatment Evaluation Units (VTEUs) and a new leadership group.
AIDS Clinical Trials Group
The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world. These investigators and units serve as the major resource for HIV/AIDS research on treatment and care for persons living with HIV/AIDS.
CoVPN Operations Centers
Vaccine Studies
Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N.
PO Box 19024
Seattle WA 98109, U.S.A.
Monoclonal Antibody (mAb) Studies
FHI 360
359 Blackwell St. Suite 200
Durham, NC 27701, U.S.A.
How to Contact Us
If you have questions about the studies, please check the Frequently Asked Questions.
The COVID-19 Prevention Network does not provide personal medical advice or diagnoses. If you are experiencing a medical emergency, call 911 and notify the operator if you think you might have COVID-19. If you think you have been exposed to COVID-19 and develop a fever and symptoms such as a cough or difficulty breathing, call your healthcare provider immediately for medical advice.
Funding Acknowledgement
This Network is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Content last reviewed on May 20, 2021